A comparative analysis on safety and efficacy of telmisartan and ramipril in treatment of hypertension in a tertiary care hospital

Wajid Gulzar; Mudasir Manzoor Dar; Amritpal Singh; Peer Samiq Masoodi; Shah Samreen; Uma Jyoti

doi:10.18203/2320-6012.ijrms20263104

Authors

Wajid Gulzar Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda, Punjab, India https://orcid.org/0009-0006-0405-5940
Mudasir Manzoor Dar Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda, Punjab, India https://orcid.org/0009-0003-1432-0806
Amritpal Singh Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India
Peer Samiq Masoodi Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda, Punjab, India https://orcid.org/0009-0006-7618-4944
Shah Samreen Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda, Punjab, India https://orcid.org/0009-0003-9061-0151
Uma Jyoti Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda, Punjab, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20263104

Keywords:

ACE inhibitors, Angiotensin receptor blockers, Antihypertensive therapy, Blood pressure control, Drug safety, Hypertension, RAAS, Ramipril, Telmisartan, Tolerability

Abstract

Background: Hypertension is a major global health challenge and an important risk factor for cardiovascular disease. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly used first-line antihypertensive agents. This study evaluated the safety and efficacy of telmisartan and ramipril in patients with hypertension at a tertiary care hospital.

Methods: This prospective observational study included 113 adult patients with hypertension who received either telmisartan (n=56) or ramipril (n=57). Pre- and post-treatment systolic (SBP) and diastolic blood pressure (DBP) were assessed. Efficacy was evaluated by achievement of target blood pressure, while safety was assessed based on adverse drug reactions. Statistical analysis was performed using the chi-square test.

Results: Both treatments significantly reduced SBP and DBP. Post-treatment SBP shifted mainly to 120-140 mmHg, while DBP improved to 76-85 mmHg. Target blood pressure was achieved more frequently with telmisartan (96.4%) than ramipril (80.7%) (χ²=6.862, p<0.05). Telmisartan was also associated with fewer cases of cough and greater improvement in symptoms such as headache and fatigue.

Conclusions: Both telmisartan and ramipril effectively reduced blood pressure. However, telmisartan was more effective in achieving target blood pressure and showed better tolerability with fewer adverse effects, suggesting it may be a preferable option, particularly for patients intolerant to ACE inhibitors.

References

World Health Organization. Hypertension Fact Sheet. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension. Accessed on 2 January 2026.

Vera-Ponce VJ, Valladolid-Sandoval LA, Ballena-Caicedo J, Zuzunaga-Montoya FE. Global prevalence of isolated systolic, isolated diastolic, and systodiastolic hypertension: a systematic review and meta-analysis. Cardiovasc Med. 2025;28(1):3.

Singh B, Cusick AS, Goyal A, Patel P. ACE Inhibitors. In: StatPearls. NCBI Bookshelf; 2025.

Cheraghi Z, Azmi-Naei B, Cheraghi P, Doosti-Irani A. The global prevalence of uncontrolled hypertension: a systematic review and meta-analysis. BMC Public Health. 2025;25(1):4259.

World Health Organization. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023.

Kario K, Okura A, Hoshide S, Mogi M. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 2024;47(5):1099-102.

Zeng X, Yang Y. Molecular mechanisms underlying vascular remodeling in hypertension. Rev Cardiovasc Med. 2024;25(2):72.

Senger N, Deshmukh S. Innovative pharmacological strategies targeting endothelial dysfunction and vascular remodelling in hypertension management: a narrative review. J Pharmacol Pharmacother. 2025;17(3):332-41.

Gallo G, Volpe M, Savoia C. Endothelial dysfunction in hypertension: current concepts and clinical implications. Front Med. 2022;8:798958.

Kaur J, Rout P. Physiology, renin angiotensin system. StatPearls; NCBI Bookshelf; 2026.

de Oliveira MG, Nadruz Jr W, Monica FZ. Endothelial and vascular smooth muscle dysfunction in hypertension. Biochem Pharmacol. 2022;205:115263.

Ferrari R. RAAS inhibition and mortality in hypertension. Glob Cardiol Sci Pract. 2013;2013(3):34.

Gallo G, Volpe M, Rubattu S. Angiotensin receptor blockers in the management of hypertension: a real-world perspective and current recommendations. Vasc Health Risk Manage. 2022:507-15.

Alcocer LA, Bryce A, De Padua Brasil D, Lara J, Cortes JM, Quesada D, et al. The pivotal role of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in hypertension management and cardiovascular and renal protection: a critical appraisal and comparison of international guidelines: Am J Cardiovasc Drugs. 2023;23(6):663-82.

Cutrell S, Alhomoud IS, Mehta A, Talasaz AH, Van Tassell B, Dixon DL. ACE-inhibitors in hypertension: a historical perspective and current insights. Curr Hypertens Rep. 2023;25(9):243-50.

Chen TY, Lin YC, Liu GY, Hung HC. Comparative effectiveness of telmisartan versus other angiotensin receptor blockers in reducing hypertension-related cerebrovascular and cardiovascular events: a real-world retrospective study using the TriNetX network. Front Cardiovasc Med. 2026;12:1715032.

Peresuodei TS, Gill A, Orji C, Reghefaoui M, Palacios MS, Nath TS. A comparative study of the safety and efficacy between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the management of hypertension: a systematic review. Cureus. 2024;16(2).

Yum Y, Kim JH, Joo HJ, Kim YH, Kim EJ. Three-year cardiovascular outcomes of telmisartan in patients with hypertension: an electronic health record-based cohort study. Am J Hypertens. 2024;37(6):429-37.

Gao Y, Mu X, Pang X. Efficacy and safety of aldosterone synthase inhibitors for uncontrolled hypertension: a meta-analysis of randomized controlled trials and systematic review. Front Pharmacol. 2025;16:1664810.

Sawant R, Suryawanshi S, Jadhav M, Barkate H, Bhushan S, Rane T. A prospective, randomized open-label study for assessment of antihypertensive effect of Telmisartan versus cilnidipine using ambulatory blood pressure monitoring (START ABPM study). Cardiol Res. 2023;14(3):211.

Borghi C, Cicero AF, Agnoletti D, Fiorini G. Pathophysiology of cough with angiotensin-converting enzyme inhibitors: how to explain within-class differences? Eur J Intern Med. 2023;110:10-5.

Ontarget Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59.